Evidence map›Paper›PMID 34421615›Full record

ArticleFrontiers in pharmacology2021

Effect of

Chao-Jung Chen, Mu-Lin Chiu, Chien-Hui Hung, Wen-Miin Liang, Mao-Wang Ho, Ting-Hsu Lin, Xiang Liu, Hsinyi Tsang, Chiu-Chu Liao, Shao-Mei Huang and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Chao-Jung ChenGenetic Center, Proteomics Core Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Mu-Lin ChiuSchool of Chinese Medicine, China Medical University, Taichung, Taiwan.
Chien-Hui HungGraduate Institute of Clinical Medical Sciences, Chang-Gung University, Taoyuan, Taiwan.
Wen-Miin LiangDepartment of Health Services Administration, China Medical University, Taichung, Taiwan.
Mao-Wang HoSection of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
Ting-Hsu LinGenetic Center, Proteomics Core Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Xiang LiuNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Hsinyi TsangNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Chiu-Chu LiaoGenetic Center, Proteomics Core Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Shao-Mei HuangGenetic Center, Proteomics Core Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Yi-Fang WuGenetic Center, Proteomics Core Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Yang-Chang WuGraduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.
Te-Mao LiSchool of Chinese Medicine, China Medical University, Taichung, Taiwan.
Fuu-Jen TsaiGenetic Center, Proteomics Core Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Ying-Ju LinGenetic Center, Proteomics Core Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
China Medical University · TWChina Medical University Hospital · TWAsia University · TWChiayi Chang Gung Memorial Hospital · TWNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chinese herbal medicines (CHMs) are widely used in Asian countries. They show multiple pharmacological activities, including antiviral activities. The 5'-long terminal repeat (LTR) region of HIV-1, required for viral transcription, is a potential drug target for HIV-1 reactivation and intrinsic cell death induction of infected or latently infected cells. Modulation of HIV-1 reactivation requires interactions between host cell proteins and viral 5'-LTR elements. By evaluation of two CHMs-

Indexed as

5′-long terminal repeatChinese herbal medicinehuman immunodeficiency virus type 1 latencynuclear regulatory proteinsX. strumarium

Identifiers

PMID34421615
PMCPMC8378250
OpenAlexW3190159538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.